Page 112 Cite

Suggested Citation: "Appendix D: Workshop Agenda." Institute of Medicine. 1998. Antimicrobial Resistance: Issues and Options. Washington, DC: The National Academies Press. doi: 10.17226/6121.

Appendix D
Workshop Agenda

NATIONAL ACADEMY OF SCIENCES INSTITUTE OF MEDICINE

FORUM ON EMERGING INFECTIONS

"Antimicrobial Resistance, Surveillance, and Response"

2101 Constitution Avenue, N.W., Washington, D.C.

July 30-31, 1997

WEDNESDAY, July 30th
9:00	WELCOME AND INTRODUCTION Joshua Lederberg, Forum Chairman
9:15	WHY ARE WE HERE? A FIRST LOOK AT THE COSTS OF ANTIMICROBIAL RESISTANCE Robert Rubin, The Lewin Group
9:30	TRACKING THE PROBLEM: APPROACHES TO SURVEILLANCE AND WHAT IS NEEDED An Overview David Bell, CDC
	The Global Perspective David Heymann, WHO
	A National Model Donald Low, Canada
	A Network for Research Karl Kristinsson, CEM/NET
	A U.S. State Perspective Michael Osterholm, Minnesota Department of Health

Page 113 Cite

Suggested Citation: "Appendix D: Workshop Agenda." Institute of Medicine. 1998. Antimicrobial Resistance: Issues and Options. Washington, DC: The National Academies Press. doi: 10.17226/6121.

10 45	INTEGRATING PRIVATE- AND PUBLIC-SECTOR SURVEILLANCE: WHAT IS HAPPENING AND WHAT IS NEEDED Rosamund Williams, WHO Renu Gupta, Bristol-Myers Squibb Laurence McCarthy, MRL Pharmaceutical Services
11:30	SURVEILLANCE AND THE LABORATORY: WHAT ARE THE ISSUES? Fred Tenover, CDC
11:45	HOW CAN THE SCIENCE HELP? Implications of Mapping the Genome Craig Venter, Institute for Genomic Research
	Molecular Detection of Genes Associated with Antimicrobial Resistance David Relman, Stanford University
12:30	LUNCH
1:30	HOW CAN THE SCIENCE HELP? (continued) High-Density Oligonucleotide Arrays Tom Gingeras, Affymetrix
	Applications of Genomics/Bioinformatics to Development of Anti-Infectives George Miller, Schering-Plough Research Institute
	A Role for New Therapeutic Approaches in Combating Antimicrobial Resistance Mich Hein, EPIcyte
	Applications of Field Surveillance (U.S. and International) Thomas Quinn, Johns Hopkins University
2:30	SOURCES OF RESISTANCE AND NOTIONS OF RESPONSE Stuart Levy, Tufts University
2:45	ISSUES OF JUDICIOUS ANTIBIOTIC USE Mitchell Cohen, CDC
3:00	ISSUES IN AND STRATEGIES FOR CLINICAL USE OF ANTIMICROBIALS Michael Marcy, Kaiser Permanente

Page 114 Cite

Suggested Citation: "Appendix D: Workshop Agenda." Institute of Medicine. 1998. Antimicrobial Resistance: Issues and Options. Washington, DC: The National Academies Press. doi: 10.17226/6121.

3:15	BREAK
3:30	RESISTANCE AND FOOD PRODUCTION: WHAT ISSUES, WHAT NEEDS?
	Concerns and Perspectives from Producers Paul Sundberg, National Pork Producers Council
	Salmonella DT104 on the Farm John Gay, Washington State University
	Concerns and Perspectives from the U.S. Department of Agriculture Bob Buchanan, USDA/ARS/ERRC Kaye Wachsmuth, USDA/FSI
	Concerns and Perspectives from the U.S. Environmental Protection Agency Mark Wilhite, EPA
4:45	DISCUSSION
5:30	ADJOURN
THURSDAY, JULY 31
8:30	OTHER CONCERNS AND MECHANISMS OF RESPONSE Legal Issues Arising from Development of Antimicrobial Resistance David Fidler, University of Indiana
	Expired Patents and the Potential of Existing Compounds^* Discussants: Gerald Mossinghoff, George Washington School of Law Vincent Ahonkhai, SmithKline Beecham
	Restricted Distribution and the Market^** General Discussion with FDA participants as resources

^*	Incentives: Developing Technologies for Emerging Infections." They were sufficiently provocative for us to feel that they merited further discussion to see what, if any, potential they might hold for stimulating new R&D and, in particular, dealing with antimicrobial resistance.
^**	Please note that although the FDA is formally listed only here, several FDA experts in specific fields were present to comment and answer questions.

Page 115 Cite

Suggested Citation: "Appendix D: Workshop Agenda." Institute of Medicine. 1998. Antimicrobial Resistance: Issues and Options. Washington, DC: The National Academies Press. doi: 10.17226/6121.